Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology by Hauert, Sabine & Bhatia, Sangeeta N.
Mechanisms of Cooperation in Cancer Nanomedicine: Towards 
Systems Nanotechnology
Sabine Hauerta,b,c and Sangeeta N. Bhatiaa,b,d,e,f
aHarvard-MIT Division of Health Sciences and Technology, Institute for Medical Engineering and 
Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
bDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 
Cambridge, MA 02139, USA
cEngineering Mathematics, University of Bristol, Bristol BS8 1TR, UK
dElectrical Engineering and Computer Science, Massachusetts Institute of Technology, 
Cambridge, MA 02139, USA
eDepartment of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA
fHoward Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 
02139, USA
Abstract
Nanoparticles are designed to selectively deliver therapeutics and diagnostics to tumors. Their 
size, shape, charge, material, coating and cargo, determine their individual functionalities. A 
systems approach could help predict the behavior of trillions of nanoparticles interacting in 
complex tumor environments. Engineering these nanosystems may lead to biomimetic strategies 
where interactions between nanoparticles and their environment give rise to cooperative behaviors 
typically seen in natural self-organized systems. Examples include nanoparticles that communicate 
the location of a tumor to amplify tumor homing, or self-assemble and disassemble to optimize 
nanoparticle transport. The challenge is to discover which nanoparticle designs lead to a desired 
systems behavior. To this end, novel nanomaterials, deep biological understanding, and 
computational tools are emerging as the next frontier.
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Cooperative nanosystems
Cancer is one of the leading causes of death worldwide. To address cancer, bioengineers are 
designing nanoparticles that can deliver treatments and diagnostics selectively to tumors [1, 
2]. Their size, typically between 5nm and 500nm, allows them to escape the leaky vessels in 
tumors [3]. Focus has been on engineering the functionalities of individual nanoparticles to: 
improve transport [4], target the tumor vasculature [5, 6] or extracellular matrix [7], deliver 
therapeutics [8, 9], diagnostics [10] or heat [11, 12] to the tumor environment, and 
reprogram cancer cells [13] or the immune system [14].
The behavior of each nanoparticle depends on its design and the resulting interactions in the 
body. The collective behavior of trillions of such nanoparticles interacting in a complex 
tumor environment can define their success as diagnostic or treatment agents [15]. 
Predicting and engineering these collective behaviors is empirical and not intuitive. For 
example, nanoparticles that are optimized to strongly bind and accumulate in cancer cells 
mostly accumulate in the first cells they encounter after leaking into the tumor environment. 
The resulting collective behavior is poor tissue penetration, with deep seeded tumor cells left 
untreated, otherwise called a binding site barrier [16–18]. Weaker nanoparticle binding, 
although detrimental to the function of the individual nanoparticle, could lead to a better 
system outcome. Further engineering these behaviors could result in emergent cooperative 
behaviors typically seen in self-organized systems.
Self-organized systems in nature, including social insects, animals, humans and cells, are 
able to perform complex behaviors, such as amplification, optimization, mapping, structure 
assembly, collective motion, synchronization and decision making, through the local 
interactions of many simple agents and their environment [19–22]. The field of swarm 
robotics [23, 24] has long taken inspiration from nature to engineer minimal robots that use 
simple rules to interact with their neighbors and local environment to solve complex real 
world problems [25–27]. Similarly, behaviors demonstrated in nanomedicine include: self-
assembly of nanoparticles to anchor imaging agents in tumors [28, 29], disassembly of 
nanoparticles to increase tissue penetration [30, 31], nanoparticles that compute the state of a 
tumor [32], nanoparticle-based remodeling of tumor environments to improve secondary 
nanoparticle transport [33], or nanoparticle signaling of tumor location to amplify the 
accumulation of other nanoparticles in tumors [34].
Even for simple nanoparticle designs, engineering and predicting the collective behavior of 
large numbers of nanoparticles that interact with complex tumor environments is non-
intuitive. Through a systems approach, bioengineers could automatically explore 
nanoparticle designs using crowdsourcing (http://nanodoc.org) and machine learning [35]. 
Bioengineers could: model the resulting collective behavior in simulation [4, 16, 17, 36], 
automatically test the best candidates experimentally through fast prototyping of both the 
nanoparticles [37, 38] and their environment [39], and finally validate the collective 
behaviors in vivo with feedback provided by high-resolution imaging [40]. Expertise in 
nanomaterials, deep understanding of cancer biology, and advances in the modeling and 
automation of nanosystems are making possible the first step in this direction.
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Lessons learned from the design of cooperative nanosystems could also prove useful in the 
engineering of natural swarmers, such as cells of the immune system [41] or synthetic 
bacteria [42], to improve tumor treatment and diagnostics. Overall, a systems approach to 
understand and engineer self-organized systems has the potential to result in behaviors that 
go beyond the functionalities of the individual agents and towards efficient, modular and 
predictable outcomes.
Nanoparticle behaviors
A large variety of nanoparticles have been engineered to deliver therapies and diagnostics to 
tumors. The design of a nanoparticle, and its interactions with the environment, defines its 
behavior. The composition of each nanoparticle can be summarized by its main features in 
terms of initial size, shape, charge, coating, cargo, and material, the combination of which 
determine its ability to move and interact with the environment (Figure 1) [43, 44].
The size of a nanoparticle has been shown to influence its circulation time, extravasation, 
interstitial diffusion and ability to be internalized by cells [45, 46]. Nanoparticles smaller 
than 5nm tend to escape the blood stream into tissues throughout the body [47, 48]. They are 
rapidly filtered by the kidneys and cleared in the urine. As a result, small nanoparticles have 
a short circulation time (on the order of minutes), rapid entry into tumors, and fast diffusion 
through the tumor tissue. Nanoparticles that reach the edge of a solid tumor can be carried 
out due to the gradient in hydrostatic pressure caused by the tumor physiology relative to the 
surrounding healthy tissue, thereby making their retention more challenging [3]. 
Nanoparticles larger than 5nm and up to 500 nm are, in some cases, able to remain in 
circulation for a longer time and accumulate in solid tumors by escaping through the 
enlarged pores in angiogenic vessels. Such passive targeting of nanoparticles due to porous 
angiogenic endothelium and dysfunctional lymphatic drainage, observed in some tumors, 
has been called the enhanced permeability and retention (EPR) effect [49]. Once in the 
tumor, the slow diffusion of larger nanoparticles and the difficulty of navigating the 
extracellular matrix tend to limit their ability to penetrate tumor tissue [50]. The size of a 
nanoparticle also limits its ability to be internalized by cells, and data indicates that different 
sizes could be trafficked via different endocytic pathways [44].
The shape and modulus of nanoparticles can also impact cellular uptake [51]. Nanoparticles 
with high aspect ratios, and particles that are rigid, have been shown to accumulate more 
slowly in macrophages than smaller, flexible particles, thereby reducing their clearance time 
from the blood. In situations where uptake is important, such as in tumor environments, 
spherical nanoparticles have thus far proven more efficient.
The charge of a nanoparticle also impacts its circulation time. Charged nanoparticles are 
rapidly opsonized and cleared by the immune system [52]. Passivating coatings such as 
polyethylene glycol have been used to shield the charge of nanoparticles, improve their 
circulation time on the order of days, and result in their accumulation in tumor tissue [43]. 
Similarly, phagocytic uptake can be minimized by coating nanoparticles with a “self-
peptide” derived from the human “don’t eat me” receptor, CD47 [53]. Once in tumor tissue, 
charged nanoparticles are preferentially taken up by tumor cells relative to uncharged 
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particles. Researchers have been addressing this dichotomy by designing nanoparticles that 
shed their neutral coatings to display a charged interior upon entering the tumor environment 
based on pH or enzymatic activity [54–56].
Beyond charge, nanoparticle surfaces can be engineered to display targeting ligands [5, 7, 
57] including peptides [58], antibodies [59], aptamers [60] and small molecules [61]. 
Receptors that are expressed at high levels on certain tumor cells can serve as targets that 
drive the binding and intracellular delivery of nanoparticles [6]. For small nanoparticles, 
targeting has proven useful in anchoring nanoparticles in the tumor environment, resulting in 
increased accumulation over time [62]. Recently, nanoparticles decorated with ligands 
expressing a CendR domain have been shown to activate the neuropilin-1 receptor and 
subsequently increase tissue penetration by initiating a trancellular, active transport pathway 
[63]. The effect can be made specific to tumor tissue by adding a targeting domain to the 
peptide. Receptors overexpressed on angiogenic endothelial cells have been used as vascular 
‘zip codes’ to direct and capture circulating nanoparticles and concentrate them in tumor 
environments [6], or can serve as an antiangiogenic target towards the normalization of the 
vascular bed [3, 64]. Nanoparticles have also been engineered to target the extracellular 
matrix (ECM), either to improve the retention of nanoparticles [65] or degrade the ECM to 
improve drug permeation in tumors [66]. Finally, nanoparticles can be engineered to target T 
cells and enhance immune responses towards tumors [14, 67].
One other design benefit that nanoparticles can offer is the capacity to shield materials that 
would otherwise be toxic or degraded in the body. The therapeutic cargo may then be 
carried to the tumor where it will be released or activated prior to local application, thereby 
minimizing systemic side effects while improving effectiveness despite low dosages. Cargos 
transported by nanoparticles include: chemotherapies [8, 9] and siRNA for knockdown of 
gene expression in tumor cells [13, 68], antiangiogenic agents [64, 69], agents that are 
disruptive to the ECM [70], imaging agents [1, 10], or adjuvants to activate the immune 
system [14].
The ability of nanoparticles to react to their environment is directly connected to their 
material composition [71]. Nanoparticles can be engineered to release cargos in an open-
loop manner at a predetermined rate based on material erosion, or cargo diffusion through 
the nanoparticle matrix or pores [72–74]. To increase the level of control, materials can 
release their cargo or change their physical properties in response to local stimuli in tumor 
microenvironments, such as pH or enzymatic activity [55, 75–77]. Energy sensitive 
materials can be activated by global signals such as magnetic fields [78–80], sound [81] or 
light [11, 82, 83], which can also power them to move, emit light or heat, or to release a 
cargo.
Overall, the ability of nanoparticles to sense, move and act in the body is determined by 
their design and interactions with the environment. Engineering the behavior of 
nanoparticles has become increasingly possible, thanks to a deepening understanding of 
biology and nanoparticle transport, and the impressive toolbox of nanoparticle modifiers 
available to bioengineers.
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Collective behaviors
In other fields, engineering collective behavior is necessary to achieve a desired system 
outcome. Engineering the collective behavior of nanoparticles may similarly lead to a better 
system outcome. Most nanoparticle systems implicitly cooperate, and each nanoparticle is 
designed to optimize its individual functionality [84]. The collective impact of the 
nanoparticles as treatment or imaging agents is assumed to be the sum of the independent 
nanoparticle effects. Understanding the system-level behavior of implicit cooperators may 
add insight that improves predictions. Emphasis could be placed on studying whether the 
nanoparticles can collectively distribute throughout a tumor environment or accumulate at 
effective levels in, or around, targeted cells [4]. Similarly, combination therapies aimed at 
preventing resistance can be composed of different types of nanoparticles that independently 
target cells in the tumor [85, 86].
Nanoparticles that physically interact have a more direct means of cooperation. These 
systems typically self-assemble or disassemble to modify their kinetics or collectively 
transport combined treatment and imaging agents to tumors. Rapidly diffusing imaging 
agents are able to anchor in tumors by binding to previously injected gold nanoparticles that 
have had time to accumulate there due to the EPR effect [29]. Similarly, small (10 nm) gold 
nanoparticles engineered to release conjugated doxorubicin in acidic tumor environments, 
can subsequently self-assemble to form larger gold aggregates that are then used for 
photothermal therapy [28, 87]. In vitro experiments show how nanoparticles that self-
assemble in response to enzymatic activity may be able to perform logic computations 
towards the diagnosis of tumor state [88]. Larger nanoparticles (100 nm) are able to 
disassemble into smaller nanoparticles once inside the tumor environment, in response to 
enzymatic activity, thereby improving their circulation time, accumulation in the tumor, and 
ability to penetrate deep in the tissue [31]. Other multi-stage nanoparticles including nested 
nanoparticles, mother ships, and nanocells are able to overcome transport barriers through 
the release of nano-based components in tumor environments [64, 89, 90].
In contrast to collective behaviors mediated by direct interactions between nanoparticles, 
many swarm systems found in nature communicate by modifying the environment. This 
concept is called stigmergy [19]. Ants deposit and sense chemical signals to form trails to 
sources of food [20]. Termites are able to build complex structures by modifying and locally 
sensing their physical environment [27]. In a similar way, nanoparticles have been designed 
to modify their physical environment or deposit chemical signals. Gold nanorods that 
accumulate in a tumor, upon heating with NIR light to sub-lethal temperatures, can improve 
perfusion of angiogenic vessels and in some cases upregulate receptors used in targeting, 
which in turn improves the delivery of a second wave of nanoparticles, such as liposomes 
and magnetic nanoworms, to tumors for treatment and imaging purposes [33, 82]. Similarly, 
nanoparticles that aim to normalize the vascular bed, or degrade the extracellular matrix can 
improve the transport of secondary nanoparticles [3, 66].
Nanoparticles can also communicate through the environment by depositing a signal 
according to two possible modes of action. In the first, nanoparticles are able to release 
either a cargo or energy, which can directly interact with other nanoparticles. This approach 
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offers an important advantage: nanoparticle communication can be engineered to be 
orthogonal to the host system. As an example, gold nanorods activated through NIR light 
emit heat in tumors to trigger the release of chemotherapeutics contained in thermally 
sensitive drug carriers [91]. Unfortunately, the scales at which nanoparticles function make 
it difficult for a chemical cargo to encounter a second nanoparticle in the environment. In 
contrast, biological systems have built-in mechanisms to amplify signals, coercing 
biological cascades can result in longer-range communication systems. Gold nanorods 
heated through NIR light can cause a clotting cascade in tumors [34]. This biological 
cascade serves as a signal to communicate the location of the tumor to circulating 
nanoparticles loaded with chemotherapeutics. To achieve this outcome, the receiving 
nanoparticle, here a liposome or nanoworm, is targeted to a byproduct of the coagulation 
cascade (the transglutaminase FXIII). This communication strategy leads to a 40-fold 
increase in the amount of chemotherapeutic delivered to the tumor when compared to a non-
communicating system [34].
Nanoparticles can cooperate implicitly, directly through self-assembly and disassembly, or 
through stigmergy (Figure 2). These behaviors have been useful to improve nanoparticle 
transport, accumulation, and distribution in tumor tissues towards treatment and diagnostic 
applications.
Systems nanotechnology
A systems approach could help engineer collective behaviors for nanoparticles (Figure 3) 
[92]. Currently, most nanoparticle systems are engineered based on the desired 
functionalities of the individual nanoparticles. Designing cooperative behaviors requires 
bioengineers to initially define the behavior that should be displayed by the nanoparticle 
collective within their environment of action. Examples include: “accumulate in all tumor 
cells at lethal levels, assuming sites of extravasation are no further than 200um from the 
cells” [16]. The challenge is then to understand which individual nanoparticle designs could 
give rise to this collective behavior.
Currently, the exploration of nanoparticle designs is conducted by experts with a deep 
knowledge of the intricacies of cancer nanomedicine. This paradigm is ideal when the 
collective behavior resulting from a given nanoparticle design and its iterations are well 
understood. When new designs are needed, or more complex collective behaviors are 
envisaged, automatic exploration tools built around machine learning and crowdsourcing 
can help. Mathematical optimization was used to explore formulations, in terms of binding 
kinetics and diffusion, which would enable targeted nanoparticles to penetrate deep into 
tumor tissues [16]. Regression analysis was used to explore the impact of nanoparticle 
structure on their ability to deliver siRNAs to tumor cells [93]. When the search space is too 
large, the power of the crowd can enable human guided exploration of nanoparticle designs. 
Crowdsourcing has been shown in the past to find solutions to complex scientific problems 
that were intractable for computers, despite their impressive processing power [94]. 
NanoDoc (http://nanodoc.org), for example, provides an online tool to crowdsource the 
design of nanoparticles. Using an iterative approach, players design nanoparticle treatments, 
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inject them into a virtual tumor, and continuously improve their design until they are able to 
achieve a desired collective behavior.
Once provided with a nanoparticle design, computer simulations and mathematical models 
can help predict their collective behavior. Analytical and Monte Carlo simulations have been 
used to predict the impact of multivalency of targeting moieties on the super-selectivity of 
nanoparticles to cancer cells [95]. Modeling the kinetics of nanoparticle populations in 
tumors has been demonstrated by several research groups using stochastic and deterministic 
approaches [16–18, 36, 96]. The models describe how nanoparticles extravasate, diffuse 
through the interstitial space, and bind to, or are internalized by cancer cells. Ideally, 
iterations between nanoparticle design and the resulting simulated behavior give rise to 
general guidelines that can be applied to nanosystems without the need to iterate at length 
experimentally.
After developing plans for an idealized nanoparticle, these designs must then be engineered. 
Most often, this step requires deep expertise, based on the state-of-the-art in the field. 
However, automatic tools can help combine nanoparticle features, such as size, coating and 
cargo in a deterministic fashion [37]. Particle replication in non-wetting templates (PRINT) 
technology offers an easy to use platform for the design and fabrication of monodisperse 
particles from a wide range of matrices with complete control over the physicochemical 
properties of the particle [38]. Combinatorial approaches in designing and synthesizing 
polymeric systems enable high-throughput synthesis and screening of nanoparticles with 
desired drug loading, retention in circulation and targeting. For this purpose, a number of 
polymer libraries have been designed [97–99]. Recent work on DNA self-assembly also 
enables the rapid prototyping of nanoscale structures [100–103].
Testing the collective behavior of nanoparticles is made challenging by the fact that the 
environment plays such an important role in the rise of emergent behaviors. In vivo 
experiments are an ideal testbed, provided that high-resolution imaging can be performed 
during the course of the experiment. Multimodal studies of tumor pathophysiology and 
nanoparticle dynamics can be performed with the help of intravital microscopy in window 
chambers [104, 105]. When in vivo experiments are not feasible, micro-devices, capable of 
capturing essential features of the tumor environment that are necessary for the emergence 
of collective nanoparticle behaviors can find utility. A tumor-on-a-chip system, in which a 
tumor-like spheroid is placed in a microfluidic channel, enables real-time analysis of 
nanoparticle kinetics at physiological flow conditions [106]. Recent technologies, including 
3D printing, scaffolding, and cell patterning, layering and self-assembly, have enabled 
construction of complex 3D-human tissues, including blood and lymph capillary networks, 
and could be used as a testbed for cooperative nanosystems in vitro [39, 107, 108].
A key grand challenge is the integration of all the technologies needed to provide a full 
pipeline - from problem definition to clinical translation.
Concluding remarks and future perspectives
Nanoparticle behaviors result from their individual designs and interactions with the 
environment. The control of a nanoparticle is enabled by changing its shape, charge, 
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material, coating and cargo. The behavior of trillions of nanoparticles in vivo determines 
their success as treatment and diagnostic agents. The field could therefore benefit from an 
increased understanding and systematic approaches to engineering the collective behavior of 
nanoparticles. Examples of self-organization in nature show that emergent behaviors arise 
when simple agents interact directly, or through the environment, and can lead to modular, 
scalable, and efficient strategies that outperform the capabilities of individual agents. Such 
concepts are already being used in other fields of engineering, such as swarm robotics.
Designing individual nanoparticles towards a desired cooperative strategy is challenging and 
could benefit from a systems approach. Such an endeavor would build on advances in 
computational exploration, simulation, high-throughput design of nanoparticles and the 
engineering of experimental testbeds in vitro and in vivo. This approach is now made 
possible thanks to advances in nanoparticle design and a deeper understanding of biology, 
which have given rise to the first instances of cooperative nanoparticles that can 
communicate tumor locations, improve transport, and self-assemble or disassemble. The 
next frontier is to learn from these examples to design biomedical systems that can perform 
complex tasks such as optimization, computation, decision-making, construction, self-
assembly and collective motion. Strategies of cooperation could go beyond nanoparticles to 
integrate engineered biological systems including synthetic bacteria and cells of the immune 
system towards biomedical applications.
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Highlights
Nanoparticle designs and interactions in the body determine their individual 
behavior.
The collective behavior of nanoparticles can be exploited to improve performance
Bio-inspired mechanisms of cooperation include self-assembly and communication.
Systems approach builds on new nanomaterials, biological insight, and computation.
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Figure 1. 
Nanoparticle Behaviors. Nanoparticle designs, in terms of size, shape, modulus, charge, 
material, surface and cargo, as well as their interactions in the body, determine their 
individual behavior.
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Figure 2. 
Mechanisms of Cooperation in Nanosystems. A) Implicit cooperation: Each nanoparticle 
works individually to improve the overall tissue distribution (top) or work as a combination 
therapy (bottom). B) Direct cooperation: Physical interactions enable nanoparticles to self-
assemble (top) and disassemble (bottom) towards improved nanoparticle transport and 
retention in tumors. C) Stigmergic cooperation: Nanoparticles interact through the 
environment by either modifying the environment to improve the transport of secondary 
nanoparticles (left), or by depositing a signal (right). Signaling nanoparticles can emit 
energy and chemicals, or coerce a biological response from the tumor environment, that can 
be received by a secondary nanoparticle.
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Figure 3. 
Systems Approach Towards Nanomedicine. A systems approach could help design the 
individual nanoparticles that would give rise to desired cooperative behaviors. This requires 
advances in computational exploration, modeling and the fast prototyping of experiments 
before validation in vivo.
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